Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
April 29, 2021 14:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting
April 15, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 15, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
April 06, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 10, 2021 06:45 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference
March 04, 2021 08:00 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences
January 04, 2021 07:30 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
December 17, 2020 06:30 ET
|
Zynerba Pharmaceuticals, Inc.
- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial - - Conference Call and Webcast Today,...
Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)
December 04, 2020 11:30 ET
|
Zynerba Pharmaceuticals, Inc.
- New Efficacy Data Describe Strong Evidence of Seizure Reduction over 12 Months of Treatment, Including a 73% Median Reduction from Baseline in Monthly Seizure Frequency at Month 12 - - Zygel™...
Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the 2020 Virtual Annual Meeting of the American Epilepsy Society (AES)
November 23, 2020 11:45 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Highlights
November 09, 2020 06:45 ET
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...